Angiogenesis and vascular targeting in Ewing sarcoma

Ewing sarcoma is the second most common type of bone cancer in children and young adults. In recent years, the mechanisms by which these tumors develop and maintain their vascular supply have been elucidated. Additional work has demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of Ewing sarcoma mouse xenografts. Early clinical data suggest that these results also may extend to patients with Ewing sarcoma who are treated with antiangiogenic or antivascular therapies. For the current review, the authors summarized the available data supporting this approach. Cancer 2010. © 2009 American Cancer Society.

[1]  P. Picci,et al.  Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[2]  D. West,et al.  Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT) , 2008 .

[3]  S. Keir,et al.  Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[4]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[5]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[6]  A. Tolcher,et al.  Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Keir,et al.  Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[8]  R. D'Amato,et al.  Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. , 2005, Current cancer drug targets.

[9]  A. Ferrari,et al.  Vinorelbine and low‐dose cyclophosphamide in the treatment of pediatric sarcomas , 2004, Cancer.

[10]  J. Blay,et al.  Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Kleinerman,et al.  VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature , 2008, Angiogenesis.

[12]  S. Donaldson,et al.  Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Jianzhong Huang,et al.  Regression of established tumors and metastases by potent vascular endothelial growth factor blockade , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Keir,et al.  Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[15]  Lothar Schweigerer,et al.  Quantification of angiogenesis stimulators in children with solid malignancies , 2001, International journal of cancer.

[16]  E. Kleinerman,et al.  Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy , 2007, Clinical Cancer Research.

[17]  E. Kleinerman,et al.  The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice , 2008, British Journal of Cancer.

[18]  Martin A. Koschat,et al.  Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. , 2001, Medical and pediatric oncology.

[19]  Amanda J. Thomas,et al.  A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer , 2005, Journal of pediatric hematology/oncology.

[20]  S. Baruchel,et al.  Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Burchill,et al.  Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours. , 2009, European journal of cancer.

[22]  C. Betsholtz,et al.  Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. , 1999, Development.

[23]  Olivier Delattre,et al.  Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. , 2005, Cancer research.

[24]  Chris L. Fryer,et al.  Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy—a report from the Children's Oncology Group , 2007, Pediatric blood & cancer.

[25]  J. Gerss,et al.  Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing's sarcoma. , 2006, European journal of cancer.

[26]  R. Janknecht,et al.  Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1 and May Represent an Independent Predictor of Survival in Ewing’s Sarcoma , 2004, Clinical Cancer Research.

[27]  A. Tolcher,et al.  A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors , 2007 .

[28]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[29]  C. Nanni,et al.  Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma , 2007, Clinical Cancer Research.

[30]  E. Kleinerman,et al.  Stromal cell‐derived factor‐1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor , 2008, International journal of cancer.

[31]  Helen X. Chen,et al.  Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Ladanyi,et al.  Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells , 2003, Oncogene.

[33]  G. Leverger,et al.  Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  C. Denny,et al.  EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. , 2007, Cancer research.

[35]  P. Leavey,et al.  Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology Group , 2008, Pediatric blood & cancer.

[36]  Wenbiao Liu,et al.  A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Inhibits Ewing's Sarcoma Growth in a Xenograft Mouse Model , 2005, Clinical Cancer Research.

[37]  S. Keir,et al.  Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[38]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[39]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[40]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[41]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[42]  E. Kleinerman,et al.  VEGF165, but not VEGF189, Stimulates Vasculogenesis and Bone Marrow Cell Migration into Ewing's Sarcoma Tumors In vivo , 2007, Molecular Cancer Research.

[43]  S. Burchill,et al.  Vascular Endothelial Growth Factor: A Therapeutic Target for Tumors of the Ewing's Sarcoma Family , 2005, Clinical Cancer Research.

[44]  E. Kleinerman,et al.  Bone Marrow Subsets Differentiate into Endothelial Cells and Pericytes Contributing to Ewing's Tumor Vessels , 2008, Molecular Cancer Research.

[45]  I. Fidler,et al.  Activation of the Platelet-Derived Growth Factor-Receptor Enhances Survival of Murine Bone Endothelial Cells 1 , 2004, Cancer Research.

[46]  D. Mikulic,et al.  Angiogenesis and Ewing sarcoma--relationship to pulmonary metastasis and survival. , 2006, Journal of pediatric surgery.

[47]  S. Schuetze,et al.  Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma , 2008 .

[48]  G. Koren,et al.  A Pilot Pharmacokinetic and Antiangiogenic Biomarker Study of Celecoxib and Low-dose Metronomic Vinblastine or Cyclophosphamide in Pediatric Recurrent Solid Tumors , 2006, Journal of pediatric hematology/oncology.

[49]  L. Ellis,et al.  Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature , 2006, International journal of cancer.

[50]  T. Fojo,et al.  Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[52]  Jianzhong Huang,et al.  Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. , 2004, International journal of oncology.